WO2024218697 - METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES
National phase entry:
Publication Number
WO/2024/218697
Publication Date
24.10.2024
International Application No.
PCT/IB2024/053769
International Filing Date
17.04.2024
Title **
[English]
METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES
[French]
MÉTHODES ET SYSTÈMES POUR AMÉLIORER DES THÉRAPIES ANTICANCÉREUSES
Applicants **
OSASUNA THERAPEUTICS SA
EPFL Innovation Park
Building F - 1st Floor
CH-1015 Lausanne, CH
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
101 Rue de Tolbiac
75013 Paris, FR
UNIVERSITÉ PARIS CITÉ
85 Boulevard Saint-Germain
75006 Paris, FR
SORBONNE UNIVERSITÉ
21 rue de l'Ecole de Médecine
75006 Paris, FR
ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS
55 Boulevard Diderot
75012 Paris, FR
INSTITUT GUSTAVE ROUSSY
39 Rue Camille Desmoulins
94805 Villejuif Cedex, FR
Inventors
DE BOER, Mark
c/o Osasuna Therapeutics SA
EPFL Innovation Park
Building F - 1st Floor
CH-1015 Lausanne, CH
KROEMER, Guido
Centre biomedical des Cordeliers
Inserm UMR1138
15 rue de l'Ecole de Medecine
75006 Paris, FR
MONTEGUT, Léa
Centre biomedical des Cordeliers
lnserm UMR1138
15 rue de l'Ecole de Medecine
75006 Paris, FR
MARTINS, Isabelle
Centre biomedical des Cordeliers
lnserm UMR1138
15 rue de l'Ecole de Medecine
75006 Paris, FR
PAN, Hui
Centre biomedical des Cordeliers
lnserm UMR1138
15 rue de l'Ecole de Medecine
75006 Paris, FR
CHEN, Hui
Centre biomedical des Cordeliers
lnserm UMR1138
15 rue de l'Ecole de Medecine
75006 Paris, FR
LI, Sijing
Centre biomedical des Cordeliers
lnserm UMR1138
15 rue de l'Ecole de Medecine
75006 Paris, FR
Priority Data
23168612.2
18.04.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 6514 | |
| EPO | Filing, Examination | 119167 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 43460 |
Total: 170306 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides improved methods, compositions, agents, therapeutic regimens, and systems for cancer treatment, such as improving the outcome of chemo- and/or immunotherapies, and/or inducing autophagy in subjects through the inhibition of extracellular diazepam binding inhibitor (DBI) by various methods.[French]
La présente divulgation concerne des méthodes, compositions, agents, régimes thérapeutiques et systèmes améliorés pour le traitement du cancer, tels que l'amélioration du résultat de chimiothérapies et/ou d'immunothérapies, et/ou l'induction de l'autophagie chez des sujets par l'inhibition d'un inhibiteur de liaison de diazépam extracellulaire (DBI) par diverses méthodes.